Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I multiple ascending dose study of RO5458640 in advanced solid tumors
NL-OMON38050Phase 1Recruiting
- Sponsor
- Roche
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of RO5458640 in Nonhematologic neoplasms, sponsored by Roche. Started Oct 2011; status: recruiting.
02
Drugs
RO5458640
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON38050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38050.